-

Confluent Medical Technologies Announces Grand Opening of Costa Rica Expansion

Confluent Medical Technologies Announces the Grand Opening of the Newest Building at Their Large Scale Manufacturing Center of Excellence in Alajuela, Costa Rica

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Confluent Medical Technologies (Confluent), today announced the Grand Opening of the latest addition to their large scale manufacturing center of excellence in Alajuela, Costa Rica, expanding their capacity for Nitinol processing and catheter manufacturing.

This new facility will be co-located with the existing Confluent Costa Rica facility and will add an additional 66,000 square feet to this location. The new site greatly expands Confluent’s capacity to process Nitinol components, as well as produce complex catheters using a combination of clean rooms and white-space manufacturing.

“Confluent has experienced consistent and strong growth in recent years,” says Confluent President & CEO Dean Schauer. “This expansion supports our new product pipeline which continues to grow at a rate greater than Confluent has previously experienced.”

Confluent supports some of the fastest growing medical device markets such as Interventional Neurovascular, Electrophysiology, Structural Heart, and Peripheral Vascular. As a result of the double-digit growth of these currently served markets, a substantial number of new products are coming into production and will utilize this new facility space immediately. Additionally, Confluent is considering additional expansion options beyond this new facility.

About Confluent Medical Technologies

Confluent Applies Materials Science to MedTech Innovation. Confluent’s engineered solutions to the most challenging design problems enable our OEM medical device customers to offer life-saving implantable products. Our customers rely on Confluent for materials science and associated manufacturing expertise which is critical to the function and value of their most demanding, high growth products – proprietary expertise which spans processing of high purity Nitinol, ultra-high density knitting of biomedical textiles, and precision laser treatment of specialty polymers. Confluent partners with leading OEMs to create a selective product portfolio which includes such complex applications as transcatheter heart valves, neurovascular implants, endovascular stent grafts, and advanced smart catheters. With facilities in Fremont and Laguna Niguel, California; Warwick, Rhode Island; Windham, Maine; Austin, Texas; Chattanooga, Tennessee; and San Jose, Costa Rica, Confluent has earned the confidence of the leaders in the medical device community through a proven track record of innovative materials science, engineering, and manufacturing.

For information please contact Confluent Medical, https://confluentmedical.com/.

Contacts

More News From Confluent Medical Technologies

Confluent Medical Technologies Names Matthew K. Eckl as Chief Financial Officer

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Confluent Medical Technologies, Inc. (“Confluent”) today announced that Matthew K. Eckl has been appointed as Chief Financial Officer ("CFO") for the company, effective October 17, 2022. "We are thrilled to welcome Matt to Confluent," said Dean Schauer, Confluent’s Chief Executive Officer. "Matt has exceptional experience in finance and financial operations as well as leadership across a variety of design and manufacturing organizations. As Confluent continue...

Confluent Medical Announces Closing of Majority Investment From TPG

SCOTTSDALE, Ariz. & SAN FRANCISCO--(BUSINESS WIRE)--The majority investment from TPG has been finalized, further strengthening Confluent Medical's leadership as a trusted medical device manufacturer....

Confluent Medical Announces Significant Strategic Investment From TPG

SCOTTSDALE, Ariz. & SAN FRANCISCO--(BUSINESS WIRE)--Confluent Medical Technologies (“Confluent”), a leading materials science, development and manufacturing partner to medical device manufacturers (“OEMs”), today announced that TPG Capital, the private equity platform of alternative asset management firm TPG, has agreed to make a majority investment in the company. TPG Capital joins existing investor Ampersand Capital Partners (“Ampersand”), which will retain a substantial minority interest in...
Back to Newsroom